AntibioticDB

NAI-107

Antimicrobial peptide (lantibiotic)

Sentinella Pharmaceuticals, Inc.
(Previously owned by NAICONS, Milan, Italy)

2009

Highest development stage: Preclinical
Development active
Gram-positive activity
Mechanism of Action/Target pathogen: MRSA (methicillin resistant Staphylococcus aureus)
Source: https://www.sciencedirect.com/science/article/pii/S1074552107004061?via%3Dihub
Citation (1): http://naicons.com/early-development-programs/
Citation (2): https://www.ncbi.nlm.nih.gov/pubmed/23657384
Citation (3): https://www.ncbi.nlm.nih.gov/pubmed/19844846